Previously, it was reported that upstream blockade of IL-1β maturation by NLRP3 inflammasome and caspase-1 inhibition reduced hepatic fibrosis, proving that lacking IL-1β in NASH may ameliorate pro-fibrotic events50–52. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.